This site is intended for US Healthcare Professionals Only.
Woven Intestine With Coral “Inflammation” and Purple “Fibrosis” Threads, “Two Key Contributors to IBD Progression, Ref 1–3."

Inflammatory bowel disease (IBD) is a chronic disease of the intestinal tract, encompassing both ulcerative colitis (UC) and Crohn’s disease (CD).1,3-5  IBD is marked by inflammation and fibrosis that can contribute to progressive tissue damage and impaired bowel function.3,5-7

In UC, serious complications may include colonic perforation and severe refractory bleeding.8

In CD, fibrosis can contribute to progressive bowel wall thickening and stricture formation, which can result in luminal narrowing and obstruction of the bowel lumen and muscle hypertrophy. Fibrostenosis can lead to a penetrating or stricturing disease course, which impairs quality of life and often requires surgical intervention.9


Maintaining sustained clinical remission has been a challenge for many adult patients with IBD.10

Expanding the Understanding of IBD as an Immuno-Fibrotic Disease3,5,6

""

Inflammatory Pathways and Fibrotic Mechanisms May Establish a Self-Perpetuating Inflammatory and Fibrotic Loop2,3,5,7

Preclinical studies suggest dysregulation of the immune system can create a cycle in which inflammation induces fibrosis, and the resulting tissue damage exacerbates the immune activation.7,13,14,a

The diagram, titled "Proposed Immuno-Fibrotic Loop," illustrates a four-stage cyclical process. Arrows connect the four stages in a clockwise direction. The cycle begins at the top left with "Immune Dysregulation," represented by a cluster of cells. An arrow points to the next stage, "Barrier Dysfunction," which shows a cross-section of an epithelial cell layer with particles passing through a gap, indicating a breach. From there, an arrow leads to "Immune Response," which displays illustrations of various immune cells, including a macrophage, a dendritic cell, and a monocyte. The final arrow points to "Chronic Inflammation & Fibroblast Activation," depicted by an inflammatory cell cluster and an activated fibroblast. This stage then connects back to the start, "Immune Dysregulation," completing the loop and suggesting a self-perpetuating process.
The diagram, titled "Proposed Immuno-Fibrotic Loop," illustrates a four-stage cyclical process. Arrows connect the four stages in a clockwise direction. The cycle begins at the top left with "Immune Dysregulation," represented by a cluster of cells. An arrow points to the next stage, "Barrier Dysfunction," which shows a cross-section of an epithelial cell layer with particles passing through a gap, indicating a breach. From there, an arrow leads to "Immune Response," which displays illustrations of various immune cells, including a macrophage, a dendritic cell, and a monocyte. The final arrow points to "Chronic Inflammation & Fibroblast Activation," depicted by an inflammatory cell cluster and an activated fibroblast. This stage then connects back to the start, "Immune Dysregulation," completing the loop and suggesting a self-perpetuating process.
The diagram, titled "Proposed Immuno-Fibrotic Loop," illustrates a four-stage cyclical process. Arrows connect the four stages in a clockwise direction. The cycle begins at the top left with "Immune Dysregulation," represented by a cluster of cells. An arrow points to the next stage, "Barrier Dysfunction," which shows a cross-section of an epithelial cell layer with particles passing through a gap, indicating a breach. From there, an arrow leads to "Immune Response," which displays illustrations of various immune cells, including a macrophage, a dendritic cell, and a monocyte. The final arrow points to "Chronic Inflammation & Fibroblast Activation," depicted by an inflammatory cell cluster and an activated fibroblast. This stage then connects back to the start, "Immune Dysregulation," completing the loop and suggesting a self-perpetuating process.

Barrier Dysfunction

Immune Response 

Chronic Inflammation & Fibroblast Activation

Immune Dysregulation

aSupport for this information is primarily based upon preclinical in vitro and animal studies.14


The Immuno-Fibrotic Impact on Inflammatory Bowel Disease Progression3,5,6

bImmuno-fibrosis is the process by which inflammation and fibroblast activation drive disease.3,5-7

cImmuno-fibrotic diseases are chronic progressive conditions marked by immune dysregulation, inflammation, and fibroblast activation. The impact of inflammation and fibrosis can vary by disease, stage, and patient.3-7

dSupport for this information is primarily based upon preclinical in vitro and animal studies.3

Fibroblast Cell With an Elongated, Spindle-Shaped Body and a Blue-Green Oval Nucleus in the CenterFibroblast Cell With an Elongated, Spindle-Shaped Body and a Blue-Green Oval Nucleus in the Center

Why Fibrosis Matters in IBD

Persistent immune activation can trigger fibroblast activity and excessive ECM deposition—a process of impaired tissue remodeling with clinical implications that include bowel wall thickening, stricture formation, and obstruction.3,15

In a retrospective study of newly diagnosed CD patients in the United States between 2017 and 2019, the percentage of patients experiencing CD progression—including intestinal obstruction/stenosis, fistula, intestinal abscess, or CD-related surgery—was 25.2% (1714/6804) over a mean (SD) follow-up of 2.3 years (0.70). 26.6% (444/1668) of newly diagnosed patients experienced CD progression by 3 years.16

In a retrospective study of adult patients with IBD in the United States, patients newly diagnosed with UC between 2007–2023 were found to have a 5-year cumulative risk of colectomy of 5.7%17

(95% CI, 4.8%–6.6%)

Submucosal fibrosis was almost exclusively detected in areas affected by active inflammation and/or chronic mucosal injury.11

Expanding Our Understanding of the Pathways That Contribute to IBD Progression

A growing body of evidence points to the contribution of both inflammatory and fibrotic pathways in IBD progression.3,5,6

Understanding Immuno-Fibrotic Pathways in IBD

IBD progression potentially involves multiple immune-mediated pathways that contribute to inflammation and fibrosis.7 A shift toward pro-inflammatory signaling—including elevated IL-1β, IL-23, IL-17A and IL-17F, alongside IL-6 trans-signaling, which has been linked to chronic intestinal inflammation—has been observed in IBD.18 Furthermore, the cytokines TGF-β, IL-1β, and IL-6 are suggested to be involved in the process of fibrogenesis.3,5,9

The Emerging Science of TL1A

Molecular Illustration of TL1A Protein, Shown as a Clustered Structure in Shades of Purple, Pink, Red, and OrangeMolecular Illustration of TL1A Protein, Shown as a Clustered Structure in Shades of Purple, Pink, Red, and Orange

TL1A Is an Amplifier of Immuno-Fibrotic Mechanisms2,e

The diagram, titled "Proposed Role of TL1A," shows a biological pathway starting with TL1A-expressing cells: Dendritic Cell, Monocyte, and Macrophage. An arrow from the Monocyte leads to the protein TL1A, which is shown interacting with its receptor, DR3. This interaction initiates a downstream process involving inflammatory and stromal cells. A group of cells, including TH1, TH2, TH17, NKT, CD8+, and CD4+ cells, are shown to be part of the adaptive and innate immunity, leading to the state of INFLAMMATION. Another group of cells, including Innate Lymphoid Cells (ILC), Macrophages, and Fibroblasts, are also involved. The diagram indicates that ILC, Macrophages, and Fibroblasts contribute to FIBROGENESIS. There is a clear progression from INFLAMMATION to FIBROGENESIS, and a feedback mechanism labeled "Immuno-Fibrotic Loop" connects these two states with bidirectional arrows, indicating a reciprocal relationship. Specific cytokines produced by certain cells are listed, such as TNF-α, IL-6, IL-13, and IL-17 by TH17 cells, and TGF-β, IL-1β, and IL-6 by Fibroblasts.
The diagram, titled "Proposed Role of TL1A," shows a biological pathway starting with TL1A-expressing cells: Dendritic Cell, Monocyte, and Macrophage. An arrow from the Monocyte leads to the protein TL1A, which is shown interacting with its receptor, DR3. This interaction initiates a downstream process involving inflammatory and stromal cells. A group of cells, including TH1, TH2, TH17, NKT, CD8+, and CD4+ cells, are shown to be part of the adaptive and innate immunity, leading to the state of INFLAMMATION. Another group of cells, including Innate Lymphoid Cells (ILC), Macrophages, and Fibroblasts, are also involved. The diagram indicates that ILC, Macrophages, and Fibroblasts contribute to FIBROGENESIS. There is a clear progression from INFLAMMATION to FIBROGENESIS, and a feedback mechanism labeled "Immuno-Fibrotic Loop" connects these two states with bidirectional arrows, indicating a reciprocal relationship. Specific cytokines produced by certain cells are listed, such as TNF-α, IL-6, IL-13, and IL-17 by TH17 cells, and TGF-β, IL-1β, and IL-6 by Fibroblasts.
The diagram, titled "Proposed Role of TL1A," shows a biological pathway starting with TL1A-expressing cells: Dendritic Cell, Monocyte, and Macrophage. An arrow from the Monocyte leads to the protein TL1A, which is shown interacting with its receptor, DR3. This interaction initiates a downstream process involving inflammatory and stromal cells. A group of cells, including TH1, TH2, TH17, NKT, CD8+, and CD4+ cells, are shown to be part of the adaptive and innate immunity, leading to the state of INFLAMMATION. Another group of cells, including Innate Lymphoid Cells (ILC), Macrophages, and Fibroblasts, are also involved. The diagram indicates that ILC, Macrophages, and Fibroblasts contribute to FIBROGENESIS. There is a clear progression from INFLAMMATION to FIBROGENESIS, and a feedback mechanism labeled "Immuno-Fibrotic Loop" connects these two states with bidirectional arrows, indicating a reciprocal relationship. Specific cytokines produced by certain cells are listed, such as TNF-α, IL-6, IL-13, and IL-17 by TH17 cells, and TGF-β, IL-1β, and IL-6 by Fibroblasts.

Abbreviations

Merck is committed to advancing the science behind immuno-fibrotic diseases and continued exploration of immuno-fibrotic pathways to deepen our understanding of IBD progression.1-3

References